Gilead Sciences’ CAR T Cell Therapy Tecartus Expanded to Treat Adult Patients with Leukemia
July 25, 2022
Trending News 🌥️
Gilead Sciences’ ($NASDAQ:GILD) CAR T cell therapy Tecartus has been expanded to treat adult patients with leukemia. The expanded approval was recommended by a committee of the European Medicines Agency. This is a significant development for Gilead, as it opens up a new market for their Tecartus therapy. It is unclear at this time how this will affect Gilead’s market and earnings in the long term.
Market Reaction
Gilead Sciences is a biopharmaceutical company that specializes in the development of drugs for the treatment of serious medical conditions. On Friday, the company’s stock opened at $61.3 and closed at $60.8. This is a significant development as CAR T cell therapy is a cutting-edge treatment option that has the potential to improve the lives of patients with leukemia.
VI Analysis
VI app makes analyzing a company’s fundamentals simple. Based on the VI Risk Rating, GILEAD SCIENCES is a medium risk investment in terms of financial and business aspects. Potential risks can be found in the business and financial areas on our website.
Summary
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. This is good news for patients and investors alike as it opens up a new market for the company’s products.
